UBS Group’s Trinity Biotech TRIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $431 | Buy |
37
+3
| +9% | +$56 | ﹤0.01% | 9855 |
|
|
2026
Q1 | $546 | Buy |
34
+8
| +31% | +$177 | ﹤0.01% | 9837 |
|
|
2025
Q4 | $617 | Buy |
26
+24
| +1,200% | +$708 | ﹤0.01% | 9874 |
|
|
2025
Q3 | $53 | Buy |
+2
| New | +$63 | ﹤0.01% | 10013 |
|
|
2025
Q1 | – | Sell |
-354
| Closed | -$9.35K | – | 10734 |
|
|
2024
Q4 | $9.35K | Buy |
+354
| New | +$14.2K | ﹤0.01% | 8364 |
|
|
2024
Q2 | – | Sell |
-173
| Closed | -$10.6K | – | 10096 |
|
|
2024
Q1 | $10.6K | Buy |
+173
| New | +$12.2K | ﹤0.01% | 7222 |
|
|
2023
Q4 | – | Sell |
-1
| Closed | -$72 | – | 9143 |
|
|
2023
Q3 | $104 | Buy |
+1
| New | +$123 | ﹤0.01% | 8876 |
|
|
2023
Q2 | – | Sell |
-81
| Closed | -$11.4K | – | 9662 |
|
|
2023
Q1 | $11.4K | Buy |
81
+78
| +2,600% | +$12.1K | ﹤0.01% | 7510 |
|
|
2022
Q4 | $466 | Sell |
3
-60
| -95% | -$10.9K | ﹤0.01% | 10172 |
|
|
2022
Q3 | $10K | Buy |
+63
| New | +$12.2K | ﹤0.01% | 8458 |
|
|
2022
Q2 | – | Sell |
-5
| Closed | -$1K | – | 10950 |
|
|
2022
Q1 | $1K | Sell |
5
-38
| -88% | -$6.57K | ﹤0.01% | 9932 |
|
|
2021
Q4 | $9K | Buy |
43
+39
| +975% | +$11.1K | ﹤0.01% | 8927 |
|
|
2021
Q3 | $1K | Sell |
4
-17
| -81% | -$5.98K | ﹤0.01% | 9247 |
|
|
2021
Q2 | $9K | Buy |
21
+17
| +425% | +$8.48K | ﹤0.01% | 8162 |
|
|
2021
Q1 | $2K | Sell |
4
-5
| -56% | -$3.61K | ﹤0.01% | 8645 |
|
|
2020
Q4 | $5K | Buy |
+9
| New | +$4.47K | ﹤0.01% | 7848 |
|
|
2020
Q2 | – | Sell |
-101
| Closed | -$17K | – | 8359 |
|
|
2020
Q1 | $17K | Buy |
101
+73
| +261% | +$11.5K | ﹤0.01% | 6597 |
|
|
2019
Q4 | $4K | Buy |
+28
| New | +$3.99K | ﹤0.01% | 7683 |
|
|
2019
Q3 | – | Sell |
-3
| Closed | -$1K | – | 8258 |
|
|
2019
Q2 | $1K | Buy |
+3
| New | +$1.07K | ﹤0.01% | 7737 |
|
|
2018
Q4 | – | Sell |
-4
| Closed | -$2K | – | 8296 |
|
|
2018
Q3 | $2K | Buy |
+4
| New | +$2.61K | ﹤0.01% | 7755 |
|
|
2018
Q2 | – | Sell |
-8
| Closed | -$6K | – | 8246 |
|
|
2018
Q1 | $6K | Buy |
8
+6
| +300% | +$4.91K | ﹤0.01% | 7162 |
|
|
2017
Q4 | $1K | Buy |
+2
| New | +$1.55K | ﹤0.01% | 7729 |
|
|
2017
Q2 | – | Sell |
-14
| Closed | -$13K | – | 7987 |
|
|
2017
Q1 | $13K | Buy |
14
+9
| +180% | +$8.44K | ﹤0.01% | 6463 |
|
|
2016
Q4 | $5K | Buy |
+5
| New | +$5.17K | ﹤0.01% | 7257 |
|
|
2016
Q3 | – | Sell |
-4
| Closed | -$7K | – | 7937 |
|
|
2016
Q2 | $7K | Sell |
4
-11
| -73% | -$18.6K | ﹤0.01% | 6989 |
|
|
2016
Q1 | $28K | Buy |
15
+13
| +650% | +$20.7K | ﹤0.01% | 5947 |
|
|
2015
Q4 | $4K | Sell |
2
-9
| -82% | -$15.9K | ﹤0.01% | 7792 |
|
|
2015
Q3 | $19K | Buy |
11
+6
| +120% | +$14.5K | ﹤0.01% | 6752 |
|
|
2015
Q2 | $13K | Sell |
5
-13
| -72% | -$33.8K | ﹤0.01% | 7268 |
|
|
2015
Q1 | $51K | Sell |
18
-6
| -25% | -$16.6K | ﹤0.01% | 6026 |
|
|
2014
Q4 | $63K | Buy |
+24
| New | +$62K | ﹤0.01% | 6206 |
|
Other funds holding TRIB
HAIM
WN
MAWA
IWA
BCM
UBS Group's TRIB Position: Q2 2026 in Review
UBS Group increased its Trinity Biotech (TRIB) stake by 8.8% in Q2 2026, buying an estimated $56 and bringing the position to 37 shares worth $431. The position accounts for ﹤0.01% of the portfolio, ranked #9855.
UBS Group first reported a position in TRIB in Q4 2014 and has held it in 31 quarters since. The position peaked at $63K in Q4 2014. 19 funds tracked by Wall St. Rank hold TRIB as of Q2 2026.
- UBS Group held 37 shares of Trinity Biotech worth $431 as of Q2 2026.
- UBS Group bought 3 Trinity Biotech shares in Q2 2026, an estimated $56.
- Trinity Biotech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9855 holding.
- UBS Group first reported a position in Trinity Biotech in Q4 2014 and has held it in 31 quarters since.
- UBS Group's Trinity Biotech position peaked at $63K in Q4 2014.
- 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.